Overview

Pathogenic germline BRCA mutations profoundly influence breast cancer risk, with carriers facing lifetime penetrance exceeding 60% and heightened vulnerability to subsequent malignancies. Genetic testing is crucial for informing prophylactic measures, surgical decisions, and therapeutic strategies, yet remains severely underutilized. This expert-led, evidence-based webcast series provides surgeons and advanced practice providers with essential skills to identify testing candidates, provide comprehensive patient counseling, and offer personalized therapy – ultimately improving outcomes for patients with hereditary breast cancer predisposition. Join Drs. Mamounas and Robson for the first webcast to hear their insights on integrating updated testing guidelines into practice.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• Apply germline mutation testing based on recently updated guidelines to identify patients at high risk of developing breast cancer and personalize preventive and treatment decisions
• Integrate alternative models in the delivery of germline testing with focus on integrating surgeons and oncology advanced practitioners in the delivery of germline testing and pre- and post- patient counseling

Target Audience

This educational activity is designed to meet the needs of breast and general surgeons and surgical advanced practice professionals who treat and manage patients with breast cancer.

Accreditation

I Integrity CE, LLC designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.